Evidence map›Paper›PMID 33958480›Full record

ArticleMolecular pharmacology2021

Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.

James J Lu, Willma E Polgar, Anika Mann, Pooja Dasgupta, Stefan Schulz, Nurulain T Zaveri

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

James J LuAstraea Therapeutics, Mountain View, California (J.J.L., W.E.P., N.T.Z.); and Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany (A.M., P.D., S.S.).
Willma E PolgarAstraea Therapeutics, Mountain View, California (J.J.L., W.E.P., N.T.Z.); and Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany (A.M., P.D., S.S.).
Anika MannAstraea Therapeutics, Mountain View, California (J.J.L., W.E.P., N.T.Z.); and Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany (A.M., P.D., S.S.).
Pooja DasguptaAstraea Therapeutics, Mountain View, California (J.J.L., W.E.P., N.T.Z.); and Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany (A.M., P.D., S.S.).
Stefan SchulzAstraea Therapeutics, Mountain View, California (J.J.L., W.E.P., N.T.Z.); and Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany (A.M., P.D., S.S.).
Nurulain T ZaveriAstraea Therapeutics, Mountain View, California (J.J.L., W.E.P., N.T.Z.); and Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany (A.M., P.D., S.S.) nurulain@astraeatherapeutics.com.
Astraea Therapeutics (United States) · USFriedrich Schiller University Jena · DEJena University Hospital · DE

Funding

Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse TherapyR01DA027811 · NIDA · ASTRAEA THERAPEUTICS, LLC · PI ZAVERI, NURULAIN T · 2009 to 2014
$3.4M
A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIESR44DA042465 · NIDA · ASTRAEA THERAPEUTICS, LLC · PI ZAVERI, NURULAIN T · 2016 to 2017
$1.5M
NIDA NIH HHS R01 DA027811NIDA NIH HHS R44 DA042465
6 · The paper itself

Abstract

Agonists at the nociceptin opioid peptide receptor (NOP) are under investigation as therapeutics for nonaddicting analgesia, opioid use disorder, Parkinson's disease, and other indications. NOP full and partial agonists have both been of interest, particularly since NOP partial agonists show a reduced propensity for behavioral disruption than NOP full agonists. Here, we investigated the in vitro pharmacological properties of chemically diverse NOP receptor agonists in assays measuring functional activation of the NOP receptor such as guanosine 5'-O-[gamma-thio]triphosphate (GTP

Indexed as

Animalsbeta-ArrestinsCell LineGene Expression RegulationGTP-Binding ProteinsHumansLigandsMolecular StructureNociceptin ReceptorPhosphorylationReceptors, OpioidSignal TransductionSmall Molecule Librariesbeta-ArrestinsGTP-Binding ProteinsLigandsNociceptin ReceptorOPRL1 protein, humanReceptors, OpioidSmall Molecule Libraries

Identifiers

PMID33958480
PMCPMC8256882
OpenAlexW3157529610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.